Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors

Journal of Hepatology

Volumn 59, Issue 6, 2013, Pages 1223-1230

  Barbier, Louise ^a   Garcia, Stéphane ^a   Cros, Jérôme ^b   Borentain, Patrick ^a   Botta Fridlund, Danielle ^a   Paradis, Valérie ^b   Le Treut, Yves Patrice ^a   Hardwigsen, Jean ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Biopsy; Graft rejection; Immunosuppressive agents; Liver transplantation; Transplantation tolerance

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BIOPSY; CALCINEURIN INHIBITORS; CNI; GRAFT REJECTION; HBV; HCV; HEPATITIS B VIRUS; HEPATITIS C VIRUS; IMMUNOSUPPRESSIVE AGENTS; LD; LFT; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LOW-DOSE; LT; MAMMALIAN TARGET OF RAPAMYCIN; MMF; MTOR; MYCOPHENOLATE MOFETIL; SD; STANDARD-DOSE; TRANSPLANTATION TOLERANCE;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CHRONIC DISEASE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84887993782     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.032     Document Type: Article

References (47)

1. R.E. Billingham, L. Brent, and P.B. Medawar Actively acquired tolerance of foreign cells Nature 172 1953 603 606
2. R.Y. Calne, P. Friend, S. Moffatt, A. Bradley, G. Hale, and J. Firth Prope tolerance, perioperative campath H1, and low-dose cyclosporin monotherapy in renal allograft recipients Lancet 351 1998 1701 1702
3. R.Y. Calne Prope tolerance - The future of organ transplantation from the laboratory to the clinic Transpl Immunol 13 2004 83 86
4. R. Cortesini, and N. Suciu-Foca The concept of «partial» clinical tolerance Transpl Immunol 13 2004 101 104
5. International working party Terminology for hepatic allograft rejection Hepatology 22 1995 648 654
6. An international panel Banff schema for grading liver allograft rejection: an international consensus document Hepatology 25 1997 658 663
7. P. Gupta, J. Hart, D. Cronin, S. Kelly, J.M. Millis, and L. Brady Risk factors for chronic rejection after pediatric liver transplantation Transplantation 72 2001 1098 1102
8. L.H. Gao, and S.S. Zheng Cytomegalovirus and chronic allograft rejection in liver transplantation World J Gastroenterol 10 2004 1857 1861
9. A.J. Demetris, D. Adams, C. Bellamy, K. Blakolmer, A. Clouston, and A.P. Dhillon Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection Hepatology 31 2000 792 799
10. D.A.H. Neil, and S.G. Hübscher Histologic and biochemical changes during the evolution of chronic rejection of liver allografts Hepatology 35 2002 639 651
11. S. Chinnakotla, R. Goldstein, N. Onaca, T. Ueno, V. Raofi, and M. Thomas Causes of mortality in 344 adult liver transplant (OLT) recipients who survived for more than 10 years Am J Transplant 3 2003 379 [abstract 886]
12. G. Garces, G. Contreras, D. Carvalho, A. Tzakis, J. Moon, and K. Ratnam Chronic kidney disease after orthotopic liver transplantation in patients receiving tacrolimus Clin Nephrol 75 2011 150 157
13. N.C. Fischer, P.G. Nightingale, B.K. Gunson, G.W. Lipkin, and J.M. Neuberger Chronic renal failure following liver transplantation: a retrospective analysis Transplantation 66 1998 59 66
14. Y. Kong, D. Wang, Y. Shang, W. Liang, X. Ling, and Z. Guo Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis PLoS One 6 2011 e24387 [Epub 2011 Sep 9]
15. M. Vivarelli, A. Cucchetti, G. La Barba, M. Ravaioli, M. Del Gaudio, and A. Lauro Liver transplantation for HCC under calcineurin inhibitors: reassessment of risk factors for tumor recurrence Ann Surg 248 2008 857 862
16. G.P. Pageaux, L. Rostaing, Y. Calmus, C. Duvoux, C. Vanlemmens, and J. Hardwigsen Mycophenolate Mofetil in combination with reduction of Calcineurin Inhibitors for chronic renal dysfunction after liver transplantation Liver Transpl 12 2006 1755 1760
17. D.C. Rockey, S.H. Caldwell, Z.D. Goodman, R.C. Nelson, and A.D. Smith AASLD. Liver biopsy Hepatology 49 2009 1017 1044
18. A.M. Krasinkas, A.J. Demetris, J.J. Poterucha, and S.C. Abraham The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers Liver Transpl 14 2008 625 632
19. P. Bedossa, and T. Poynard An algorithm in the grading of activity in chronic hepatitis C. The METAVIR cooperative study group Hepatology 24 1996 289 293
20. G. Vervoort, H.L. Willems, and J.F. Wetzels Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients@: validity of a new (MDRD) prediction equation Nephrol Dial Transplant 17 2002 1909 1913
21. G.V. Mazariegos, J. Reyes, I. Marino, B. Flynn, J.J. Fung, and T.E. Starzl Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up Transplant Proc 29 1997 1174 1177
22. R. Girlanda, M. Rela, R. Williams, J.G. O'Grady, and N.D. Heaton Long-term outcome of immunosuppression withdrawal after liver transplantation Transplant Proc 37 2005 1708 1709
23. G. Tisone, G. Orlando, A. Cardillo, G. Palmieri, T.M. Manzia, and L. Baiocchi Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence J Hepatol 44 2006 702 709
24. T.E. Starzl, N. Murase, K. Abu-Elmagd, E.A. Gray, R. Shapiro, and B. Eghtesad Tolerogenic immunosuppression for organ transplantation Lancet 361 2003 1502 1510
25. J.D. Eason, A.J. Cohen, S. Nair, T. Alcantera, and G.E. Loss Tolerance: is it worth the risk? Transplantation 79 2005 1157 1159
26. P. Tryphonopoulos, A.G. Tzakis, D. Weppler, R. Garcia-Morales, T. Kato, and J.R. Madariaga The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation Am J Transplant 5 2005 608 613
27. G. Orlando, S. Soker, and K. Wood Operational tolerance after liver transplantation J Hepatol 50 2009 1247 1257
28. Banff working group on liver allograft pathology Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance Liver Transpl 18 2012 1154 1170
29. A. Marcos, B. Eghtesad, J.J. Fung, P. Fontes, K. Patel, and M. Devera Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus Transplantation 78 2004 966 971
30. A.G. Tzakis, P. Tryphonopoulos, T. Kato, S. Nishida, D.M. Levi, and J.R. Madariaga Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation Transplantation 77 2004 1209 1214
31. N. De Ruvo, A. Cucchetti, A. Lauro, M. Masetti, N. Cautero, and F. Di Benedetto Preliminary results of a «prope» tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation Transplantation 80 2005 8 12
32. T. Soliman, H. Hetz, C. Burghuber, G. Györi, G. Silberhumer, and R. Steininger Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation Liver Transpl 13 2007 1039 1044
33. I. Bajjoka, L. Hsaiky, K. Brown, and M. Abouljoud Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors Liver Transpl 14 2008 66 72
34. C.L. Liu, S.T. Fan, C.M. Lo, S.C. Chan, I.O. Ng, and C.L. Lai Interleukin-2 receptor antibpdy (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage Liver Transpl 10 2004 728 733
35. F. Saliba, S. Dharancy, R. Lorho, F. Conti, S. Radenne, and M. Neau-Cransac Conversion to everolimus in maintenance liver transplant patients: a multicenter retrospective analysis Liver Transpl 17 2011 905 913
36. A. Barkmann, B. Nashan, H.H. Schmidt, K.H. Böker, N. Emmanouilidis, and J. Rosenau Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil Transplantation 69 2000 1886 1890
37. L. Fischer, J. Klempnauer, S. Beckebaum, H.J. Metselaar, P. Neuhaus, and P. Schemmer A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT Am J Transplant 12 2012 1855 1865
38. P. De Simone, F. Nevens, L. De Carlis, H.J. Metselaar, S. Beckebaum, and F. Saliba Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial Am J Transplant 12 2012 3008 3020
39. K. Boudjema, C. Camus, F. Saliba, Y. Calmus, E. Salamé, and G. Pageaux Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study Am J Transplant 11 2011 965 976
40. G. Mells, and J. Neuberger Protocol liver allograft biopsies Transplantation 85 2008 1686 1692
41. M. Sebagh, K. Rifai, C. Féray, F. Yilmaz, B. Falissard, and B. Roche All liver recipients benefit from the protocol 10-year liver biopsies Hepatology 37 2003 1293 1301
42. S.C. Abraham, J.J. Poterucha, C.B. Rosen, A.J. Demetris, and A.M. Krasinskas Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests Am J Surg Pathol 32 2008 965 973
43. G. Mells, C. Mann, S. Hubscher, and J. Neuberger Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl 15 2009 931 938
44. M. Sebagh, D. Samuel, T.M. Antonini, A. Coilly, D.D. Esposti, and B. Roche Twenty-year protocol liver biopsies: invasive but iseful for the management of liver recipients J Hepatol 56 2012 840 847
45. S.C. Abraham, D.K. Freese, M.B. Ishitani, A.M. Krasinskas, and T.T. Wu Significance of central perivenulitis in pediatric liver transplantation Am J Surg Pathol 32 2008 1479 1488
46. A. Shaked, S. Feng, J. Punch, J. Reyes, and J. Levitsky Klint- Malm G, et al. Lessons learned from the ITN030ST immunosuppression withdrawal (ISW) trial in liver transplant recipients [abstract] Liver Transpl 17 2011 S84
47. P. Porrett, and A. Shaked The failure of immunosuppression withdrawal: Patient benefit is not detectable, inducible, or reproducible Liver Transpl 17 2011 S66 S68